000089941 001__ 89941
000089941 005__ 20210902121745.0
000089941 0247_ $$2doi$$a10.3389/fimmu.2020.00872
000089941 0248_ $$2sideral$$a118406
000089941 037__ $$aART-2020-118406
000089941 041__ $$aeng
000089941 100__ $$0(orcid)0000-0002-5175-8394$$aAnel, A.$$uUniversidad de Zaragoza
000089941 245__ $$aEditorial: The Natural Killer Cell Interactome in the Tumor Microenvironment: Basic Concepts and Clinical Application
000089941 260__ $$c2020
000089941 5060_ $$aAccess copy available to the general public$$fUnrestricted
000089941 5203_ $$aNK cell activity is impaired in cancer patients, supporting the use of adoptive NK cell therapy, which is becoming a credible immunotherapy for hematological malignancies. This is even more so the case after the presentation of the first clinical study using anti-CD19 NK CAR cells, which showed a good clinical activity in the absence of toxicity. The possibility of targeting solid tumors is being studied by numerous laboratories, but the tumor microenvironment supports immune suppression. Unveiling the molecular and cellular mechanisms explaining this immunosuppression is a major goal.
For this special issue, we pointed to several specific subjects, such as the metabolic interactions of NK cells with tumor targets that would regulate their function or novel molecular strategies for generating off-the-shelf NK cell cancer immunotherapies. A total of 10 manuscripts have been accepted for publication, of which five are original research and five are reviews or minireviews. Regarding the original research articles, Alvarez et al. have described the indirect contribution of the PD-1/PD-L1 system to the regulation of NK cell exhaustion using an in vivo murine model. They showed that a PD-1 blockade increased CD8+ T cell activation rates, which competed for IL-2 and resources with NK cells, retarding their activation but also their subsequent exhaustion. Federici et al. developed an exhaustive work characterizing NK-cell derived extracellular vesicles (NKEVs), separating true exosomes from microvesicles...
000089941 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000089941 590__ $$a7.561$$b2020
000089941 591__ $$aIMMUNOLOGY$$b24 / 162 = 0.148$$c2020$$dQ1$$eT1
000089941 592__ $$a2.645$$b2020
000089941 593__ $$aImmunology and Allergy$$c2020$$dQ1
000089941 593__ $$aImmunology$$c2020$$dQ1
000089941 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/publishedVersion
000089941 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J.$$uUniversidad de Zaragoza
000089941 700__ $$aVillalba, M.
000089941 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000089941 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000089941 773__ $$g11 (2020), 872 [2 pp]$$pFront. immunol.$$tFRONTIERS IN IMMUNOLOGY$$x1664-3224
000089941 8564_ $$s66114$$uhttps://zaguan.unizar.es/record/89941/files/texto_completo.pdf$$yVersión publicada
000089941 8564_ $$s29910$$uhttps://zaguan.unizar.es/record/89941/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000089941 909CO $$ooai:zaguan.unizar.es:89941$$particulos$$pdriver
000089941 951__ $$a2021-09-02-09:46:02
000089941 980__ $$aARTICLE